TITLE

The Global Map of Biosimilars in 2014

AUTHOR(S)
Galbraith, Daniel
PUB. DATE
April 2014
SOURCE
Pharmaceutical Processing;Apr2014, Vol. 29 Issue 4, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the importance placed among pharmaceutical companies on biologics. Noted are the disadvantages of biologic drugs such as the length of time and the cost associated to development and production while indicated is one benefit, which is the protection among manufacturers on market share as costs and time of developing alternative products present barriers to competition. Indicated is the emergence of developing generic biologics called biosimilars using innovator molecule.
ACCESSION #
95420391

 

Related Articles

  • Authorized generics yielding controversy, profits for drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p22 

    Reports on the future of authorized generics in the U.S. Penetration of generic products in the market; Focus of the generic drug maker; Presence of authorized generics in the market.

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • Generic Biotech Picking Up Steam.  // Drug Discovery & Development;Apr2009, Vol. 12 Issue 4, p8 

    The article reports on the rise in the use of generic biotech drugs instead of biotech drugs in the U.S. Proposal for increasing the use of generic drugs was made in March 2009 and a bill related to the issue has been passed by representative Henry A. Mazman. The bill allots only five year time...

  • First-time generic approvals.  // Formulary;Feb2004, Vol. 39 Issue 2, p80 

    Presents first-time generic approvals by the U.S. Food and Drug Administration as of February 2004. Fenoldopam injection; Amiodarone tablets; Amoxicillin tablets; Others.

  • Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development". Hollis, Aidan // PharmacoEconomics;2005, Vol. 23 Issue 12, p1187 

    The article presents and explores some useful empirical facts about 'me-too' drugs. These drugs, which are sometimes called follow-on drugs, are products that largely duplicate the action of existing drugs. Pharmaceutical industry players are becoming concern regarding the increasing extent to...

  • Pharma faces its own hurricane season. Dearment, Alaric // Drug Store News;9/19/2011, Vol. 33 Issue 12, p16 

    The article offers information on the problem faced by branded drug companies as 102 billion dollars worth of generic drugs are forecasted to face a competition between 2011 and 2015 according to IMS Health Inc. It mentions that branded drug companies will be affected and must find a way to...

  • SEE pharmaceutical market healthy in 2010. Stamov, Valentin; Pavlova, Iskra // SEE Top 100;2011, p46 

    The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics